Overview

Phase 3 Study on the Efficacy and Safety of Human Plasma Derived Antithrombin (Atenativ) in Heparin-resistant Patients Scheduled to Undergo Cardiac Surgery Necessitating Cardiopulmonary Bypass

Status:
Not yet recruiting

Trial end date:
2026-09-01

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to evaluate the efficacy of two different doses of Atenativ, versus placebo, in restoring heparin responsiveness in adult patients undergoing cardiopulmonary bypass (CPB) for cardiac surgery.

Phase:

Phase 3

Details

Lead Sponsor:

Octapharma

Treatments:

Antithrombin III
Antithrombins